stockrowPrecigen, Inc.
PGEN Healthcare Biotechnology
Precigen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.7 million, up 146.7% from fiscal 2024.
- Revenue
- +2,437.6%
- EPS
- +109.4%
- Free cash flow
- +140.3%
- Total debt
- +1.47%
Quarter to September 2026, against a year earlier
Follow PGEN
Alert me
Precigen, Inc. (PGEN) EV/Sales
As of 6 November 2026, Precigen, Inc. (PGEN) trades at a EV/Sales of 10.5×. Over the past ten years it has ranged from −126× (April 2022) to 24,389× (July 2021); the current reading is higher than 35% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 136× | 140.57% |
| FY2024 | 56.5× | 16.58% |
| FY2023 | 48.5× | 427.47% |
| FY2022 | 9.2× | (83.70%) |
| FY2021 | 56.4× | 1.64% |
| FY2020 | 55.5× | 409.90% |
| FY2019 | 10.9× | 97.03% |
| FY2018 | 5.5× | (21.42%) |
| FY2017 | 7.0× | (50.03%) |
| FY2016 | 14.1× | (20.93%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 19.9× | (18.78%) |
| Jun 2026 | 24.5× | (45.48%) |
| Mar 2026 | 45.0× | (66.91%) |
| Dec 2025 | 136× | (13.84%) |
| 43 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BRVE Braveheart Bio, Inc. compare | n/m |
| RARE Ultragenyx Pharmaceutical Inc. compare | 1.8× |
| IMCR Immunocore Holdings PLC Sponsored ADR compare | 2.6× |
| NUVB Nuvation Bio Inc. compare | 5.4× |
| PGEN Precigen, Inc. | 10.5× |
| NTLA Intellia Therapeutics, Inc. compare | 20.9× |
| QURE uniQure N.V. compare | 44.7× |
| NBTX Nanobiotix S.A. - Sponsored ADR compare | 5,356× |
| ADRX ADARx Pharmaceuticals, Inc. compare | — |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)